TrialClinical pharmacology and therapeutics2021

Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.

Geraldine Ferron-Brady et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.